22
Views
2
CrossRef citations to date
0
Altmetric
Research Article

CPH 82 (Reumacon ) in refractory inflammatory arthritis

Pages 323-325 | Published online: 12 Jul 2009
 

Abstract

In this retrospective analysis of the DMARD CPH 82 in 44 Icelandic patients with severe refractory arthritis, clinical tolerance was good and serious side effects absent, although the majority were using the drug in combination with other DMARDS. Side effects leading to discontinuation were seen in 16% and the three year drug-survival was 51%.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.